Bonney Michael W's Form 4 filing
Alnylam Pharmaceuticals, Inc. (ALNY) · filed Aug 19, 2025
- Accession no.
- 0001735276-25-000087
- Filed
- Aug 19, 2025
- Trade date
- Aug 18, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $5.06M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bonney Michael WCIK 0001219016 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2025 | Common Stock | MOption exerciseAcquired | +11,250 | $70.20 | +$789,750 | 28,054 | Direct | |
| Aug 18, 2025 | Common Stock | SSaleDisposed | −11,250 | $450.00 | −$5,062,500 | 16,804 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2025 | Common Stock | MOption exerciseDisposed | −11,250 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.